Kazia Therapeutics Annual Reports 2023

71 Kazia Theraputics Limited Annual Report 2023 Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports Note 28. Parent entity information Set out below is the supplementary information about the parent entity. Statement of profit or loss and other comprehensive income Parent 2023 2022 restated $ $ Loss after income tax (20,862,826) (24,240,776) Total comprehensive income (20,862,826) (24,240,776) Statement of financial position Parent 2023 2022 restated $ $ Total current assets 4,645,440 7,736,217 Total assets 21,914,872 26,875,108 Total current liabilities 7,003,013 2,931,452 Total liabilities 15,472,387 13,700,757 Equity Contributed equity 97,452,246 84,480,249 Reserves 4,422,666 3,263,703 Accumulated losses (95,432,427) (74,569,601) Total equity 6,442,485 13,174,351 Reserves comprise Share Based Payments Reserve. Contingent liabilities The parent entity contingent liabilities as at 30 June 2023 and 30 June 2022 are as set out in note 18. Capital commitments - Property, plant and equipment The parent entity had no capital commitments for property, plant and equipment at as 30 June 2023 and 30 June 2022. Significant accounting policies The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following: • Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. • Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

RkJQdWJsaXNoZXIy MjE2NDg3